LeMaitre Joins NASDAQ Dividend Achievers Index – 10 Years of Dividend Increases

BURLINGTON, Mass., March 21, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it has joined the NASDAQ US Broad Dividend Achievers Index. The index is comprised of US securities with at least ten consecutive years of increasing annual regular dividend payments. In 2011, LeMaitre’s first year of dividends, the annual payout per share was $0.08. In 2021, LeMaitre paid $0.44 per share, representing 18.6% compounded annual dividend growth over the decade. A further increase was announced in February 2022, bringing the quarterly payout to $0.125 per share, payable on March 24, 2022.

George W. LeMaitre, Chairman and Chief Executive Officer, said, “We’re pleased to see NASDAQ add us to their prestigious Dividend Achievers Index, a select group of 373 companies. Our growing profitability has enabled us to consistently increase our dividends since 2011. By paying dividends we re-affirm our commitment to profitability and an improving balance sheet.”

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc., and the NASDAQ US Broad Dividend Achievers Index is a registered trademark of Nasdaq.

For more information about the Company, please visit http://www.lemaitre.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the risk that we may not be able to maintain our recent levels of profitability; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the status of our global regulatory approvals and compliance with foreign regulatory requirements to market and sell our products outside the United States; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT: Contact: LeMaitre Vascular, Inc. Sandra Millar +1-781-425-1686 [email protected]

Disclaimer: This content is distributed by The GlobeNewswire